MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
MAXCYTE, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.30+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $138.87M
- P/E (TTM)
- –
- Dividend yield
- –
Maxcyte statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Services-Commercial Physical & Biological Research companies for comparison
Valuation
| Measure | Maxcyte | Industry median |
|---|---|---|
| Market Cap | $134.17M | $74.60M |
| Enterprise Value | $28.48M | $56.72M |
| PS Ratio | 4.32 | 3.25 |
| PB Ratio | 0.85 | 3.13 |
| P/TBV Ratio | 0.85 | 8.30 |
Enterprise value
| Measure | Maxcyte | Industry median |
|---|---|---|
| EV / Sales | 0.92 | 2.79 |
Income (trailing twelve months)
| Measure | Maxcyte | Industry median |
|---|---|---|
| Revenue | $31.05M | $24.74M |
| Gross Profit | $24.60M | $19.54M |
| Operating Income | -$41.79M | -$55.64K |
| Pretax Income | -$35.64M | $45.62K |
| Net Income | -$35.64M | -$97.64K |
| EBITDA | -$37.68M | -$29.48K |
| EPS (Diluted) | -$0.33 | $0.00 |
Margins
| Measure | Maxcyte | Industry median |
|---|---|---|
| Gross Margin | 79.2% | 40.4% |
| Operating Margin | -134.6% | 0.94% |
| Pretax Margin | -114.8% | 2.64% |
| Profit Margin | -114.8% | 0.51% |
| EBITDA Margin | -121.3% | 3.48% |
| FCF Margin | -76.1% | 5.05% |
Returns
| Measure | Maxcyte | Industry median |
|---|---|---|
| Return on Equity (ROE) | -20.4% | 0.45% |
| Return on Assets (ROA) | -17.6% | -3.47% |
| Return on Invested Capital (ROIC) | -56.3% | 2.85% |
| Return on Capital Employed (ROCE) | -23.9% | 2.03% |
Growth
| Measure | Maxcyte | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -13.2% | 4.26% |
| Revenue Growth (3Y CAGR) | -9.30% | 2.15% |
| Revenue Growth (5Y CAGR) | 4.76% | 7.37% |
Balance sheet
| Measure | Maxcyte | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $105.69M | $5.43M |
| Net Cash (Debt) | $105.69M | $17.62K |
| Net Cash Per Share | $1.02 | $0.00 |
| Equity (Book Value) | $158.75M | $10.50M |
| Book Value Per Share | $1.54 | $0.60 |
| Tangible Book Value | $157.99M | -$78.36K |
| Working Capital | $111.38M | $2.78M |
Financial position
| Measure | Maxcyte | Industry median |
|---|---|---|
| Current Ratio | 12.26 | 1.26 |
| Quick Ratio | 11.08 | 0.65 |
Cash flow (trailing twelve months)
| Measure | Maxcyte | Industry median |
|---|---|---|
| Operating Cash Flow | -$22.98M | $8.04K |
| Capital Expenditures | -$665.00K | -$8.33M |
| Free Cash Flow | -$23.64M | $11.03M |
| FCF Per Share | -$0.23 | $0.76 |
Efficiency
| Measure | Maxcyte | Industry median |
|---|---|---|
| Asset Turnover | 0.15 | 0.83 |
| Inventory Turnover | 0.82 | 13.10 |
| Revenue Per Employee | $341.22K | $216.23K |
| Profits Per Employee | -$391.60K | -$3.19K |
| Employee Count | 91 | 123 |
Dividends and yields
| Measure | Maxcyte | Industry median |
|---|---|---|
| Earnings Yield | -26.6% | -0.97% |
| FCF Yield | -17.6% | 3.90% |
Shares
| Measure | Maxcyte | Industry median |
|---|---|---|
| Shares Outstanding | 103,206,000 | 29,217,800 |
| Shares Change (YoY) | 0.95% | 0.84% |
| Shares Change (QoQ) | -0.92% | 0.00% |
| Float | 94,823,700 | 26,226,050 |
| Shares Held by Insiders | 8.12% | 4.85% |
| Shares Held by Institutions | 61.3% | 83.3% |
Scores
| Measure | Maxcyte | Industry median |
|---|---|---|
| Altman Z-Score | 1.17 | 2.66 |
| Piotroski F-Score | 2 | 5 |
| Beneish M-Score | -2.73 | -2.75 |
Calculated by StockData from Maxcyte's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.